A small-molecule TrkB ligand restores hippocampal synaptic plasticity and object location memory in Rett syndrome mice

Wei Li¹, Alba Bellot-Saez¹, Mary L. Phillips¹, Tao Yang², Frank M. Longo² and Lucas Pozzo-Miller¹,*

ABSTRACT

Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutations in methyl-CpG-binding protein-2 (MECP2), a transcriptional regulator of many genes, including brain-derived neurotrophic factor (BDNF). BDNF levels are reduced in RTT autopsy brains and in multiple brain areas of MeCP2-deficient mice. Furthermore, experimental interventions that increase BDNF levels improve RTT-like phenotypes in MeCP2 mutant mice. Here, we characterized the actions of a small-molecule ligand of the BDNF receptor TrkB in hippocampal function in MeCP2 mutant mice. Systemic treatment of female MeCP2 heterozygous (HET) mice with LM22A-4 for 4 weeks improved hippocampal-dependent object location memory and restored hippocampal long-term potentiation (LTP). Mechanistically, LM22A-4 acts to dampen hyperactive hippocampal network activity, reduce the frequency and amplitude of miniature excitatory postsynaptic currents (mEPSCs), and reduce the frequency of spontaneous tetrodotoxin-resistant Ca²⁺ signals in MeCP2 mutant hippocampal neurons, making them comparable to those features observed in wild-type neurons. Together, these observations indicate that LM22A-4 is a promising therapeutic candidate for the treatment of hippocampal dysfunction in RTT.

KEY WORDS: BDNF, LM22A-4, MeCP2, LTP, Voltage-sensitive dye imaging, Ca²⁺ imaging, Object location memory, CA1 pyramidal neuron

INTRODUCTION

Rett syndrome (RTT) is an X chromosome-linked neurodevelopmental disorder that affects approximately 1:10,000 females worldwide (Neul et al., 2010). RTT individuals develop typically until 6-18 months, when neurological symptoms, including intellectual disability, autistic features, deficits in motor control and sensory perception, breathing irregularities and epilepsy disorders begin (Percy, 2011). The majority of RTT individuals carry loss-of-function mutations in methyl-CpG-binding protein-2 (MECP2), which encodes the transcriptional regulator MeCP2 (Amir et al., 1999). MeCP2-deficient mice recapitulate several neurological features of RTT, including impaired hippocampal-dependent learning and memory (Calfa et al., 2011b; Li and Pozzo-Miller, 2012), which makes them useful experimental models for preclinical studies (Katz et al., 2012).

One prominent target of MeCP2 transcriptional regulation is the gene encoding brain-derived neurotrophic factor (BDNF) (Chahrour et al., 2008; Chen et al., 2003; Martinowich et al., 2003), a neurotrophin that plays critical roles in neuronal survival, differentiation, and synapse formation and plasticity (Park and Poo, 2013). BDNF levels are lower in RTT autopsy brains (Abuhazira et al., 2007; Deng et al., 2007) and MeCP2-deficient mice (Chang et al., 2006; Li et al., 2012; Schmid et al., 2012; Wang et al., 2006). Since Bdnf overexpression in male MeCP2 knockout (KO) mice rescues several RTT-like neurological and motor symptoms (Chang et al., 2006), enhancement of BDNF signaling is considered a potentially useful therapeutic approach for RTT (Katz, 2014). Owing to its low blood-brain barrier permeability that limits the bioavailability of peripherally administered BDNF, therapeutic approaches have relied on BDNF ‘mimetics’. One approach involved the use of ampakines, which are known to increase Bdnf expression by their action on AMPA-type glutamate receptors (Lauterborn et al., 2000). Peripheral treatment with ampakines significantly improved respiratory dysfunction in male MeCP2 KO mice (Ogier et al., 2007). A more direct approach is to activate TrkB receptors with small-molecule mimetics of the BDNF loop domain that are designed in silico to interact with their BDNF binding pocket (Massa et al., 2010). One such TrkB ligand with partial agonist activity, LM22A-4, reduced synaptic hyperactivity within respiratory centers in the brainstem, and improved respiratory function in female MeCP2 heterozygous (HET) mice (Kron et al., 2014; Schmid et al., 2012).

Here, we describe how a 4-week systemic LM22A-4 treatment in symptomatic female MeCP2 HET mice improved general phenotype, motor activity and hippocampal-dependent object location memory by activating the BDNF receptor TrkB. Long-term potentiation (LTP) of hippocampal excitatory synaptic transmission, the cellular substrate of learning and memory, was also restored by LM22A-4 treatment in MeCP2 HET mice. Furthermore, LM22A-4 reduced the spatio-temporal spread of neuronal depolarizations in hippocampal slices from MeCP2 HET mice to levels comparable to wild-type (WT) littermates, thus preventing network hyperactivity. In addition, LM22A-4 reduced the frequency and amplitude of miniature excitatory postsynaptic currents (mEPSCs) in CA1 pyramidal neurons of organotypic slices from MeCP2 KO mice. Finally, LM22A-4 reduced the frequency of spontaneous Ca²⁺ signals, reflecting quantal transmitter release in cultured hippocampal MeCP2 KO neurons. Together, these observations indicate that LM22A-4 is a promising therapeutic candidate for the treatment of hippocampal dysfunction in RTT.

RESULTS

LM22A-4 improves general phenotypes, motor activity and hippocampal-dependent memory in female MeCP2 heterozygous mice

Because RTT occurs primarily in females, we chose to study the effects of a chronic peripheral treatment with LM22A-4 in female MeCP2 HET mice. In additional experiments, we used male MeCP2

---

Received 13 March 2017; Accepted 8 May 2017
KO mice that are homogenously deficient in MeCP2 expression to investigate the underlying cellular mechanisms of LM22A-4 actions. Following an established and successful dosing regime (Kron et al., 2014; Schmid et al., 2012), 4-month-old female Mecp2 HET mice and age-matched WT littermates received intraperitoneal (i.p.) injections of LM22A-4 (50 mg/kg) twice daily for 1 or 2 months. During the treatment, weight and general phenotypes were assessed every week. At the end of the treatment, animals were examined for motor function and then sacrificed under deep anesthesia for assessment of activation of TrkB receptors and their downstream signaling.

Female Mecp2 HET mice of the Jaenisch strain typically exhibit an increase in body weight during the symptomatic stage (Chen et al., 2001) (Fig. 1A; WT control, n=10; Mecp2 HET control, n=9). LM22A-4 treatment had no significant effect on body weight in WT and Mecp2 HET mice (Fig. 1A; WT LM22A-4, n=10; Mecp2 HET LM22A-4, n=11). We also scored RTT-like general symptoms consisting of ill-groomed condition, reduced motility, imbalanced gait, hindlimb clasping, irregular breathing and tremor (Guy et al., 2007). Each category was scored (0: absent; 1: moderate; 2: severe), and the aggregated value showed overall phenotypes. LM22A-4 significantly reduced the score value in Mecp2 HET mice especially during the early phase of the treatment (Fig. 1B; P<0.001, two-way repeated measures ANOVA), but did not affect WT mice.

To assess general locomotor activity, we performed an open field test and measured the distance traveled during a 10 min period. We found that Mecp2 HET mice traveled significantly shorter distances than WT mice (Fig. 1C; WT control, n=9; Mecp2 HET control, n=7; P<0.01, one-way ANOVA), and that LM22A-4 treatment increased it to levels comparable with the WT (n=7; P<0.05 vs Mecp2 HET control). However, LM22A-4 had no effect on the distance traveled by WT mice (n=9). Next, we performed dowel crossings to evaluate motor coordination. Mecp2 HET mice took longer than the WT control to walk off the elevated dowel (Fig. 1D; P<0.05, one-way ANOVA), which was slightly reduced by LM22A-4 treatment.

In a different set of experiments, we performed the object location task to evaluate hippocampal-dependent spatial memory (Barker and Warburton, 2011). During the acquisition phase, animals normally show equal preference for two objects that are placed in an arena, while they exhibit a higher preference for the moved object during the subsequent test phase. The object location memory can thus be estimated by calculating the location preference index (time spent on moved objects over total time spent on two objects). As expected, the preference index in female WT mice was larger for the moved object during the test phase than the acquisition phase.

Fig. 1. LM22A-4 improves general phenotypes in Mecp2 HET mice. (A) Body weight measured every week in female WT and Mecp2 HET mice during treatment with vehicle or LM22A-4. (B) Progression of average phenotype scores in WT and Mecp2 HET mice treated with vehicle or LM22A-4. Inset shows an individual raster plot of score progression in Mecp2 HET control (top) and LM22A-4 (bottom) groups. Black denotes death of that mouse. (C) Average distance traveled in a 60×60 cm arena during a 10 min period. (D) Average falling latency from an elevated dowel. (E) WT and Mecp2 HET mice were exposed to two identical objects for 5 min during the acquisition phase, and 2 h later underwent the test trial in which one object was moved to a new location. Object location test was carried out before (top) and after (bottom) 1 month treatment with vehicle or LM22A-4. (F) Quantitative analyses of the levels of phosphorylated TrkB (p-TrkB[Y816]) relative to the total full-length (TrkB.FL) protein in hippocampal homogenates. Top panel shows representative examples of western immunoblots for p-TrkB[Y816], TrkB.FL and the internal control β-actin. Data are mean±s.e.m. *P<0.05, **P<0.01.
(Fig. 1E; top; n=7; P<0.01, paired t-test). However, we did not observe any increase in Mecp2 HET mice (n=7), suggesting an impairment of object location memory. Interestingly, systemic LM22A-4 treatment for 4 weeks significantly enhanced the preference index for the moved object in Mecp2 HET mice (Fig. 1E; bottom; n=7; P<0.05, paired t-test), but was unable to further promote it in WT mice (n=7).

To confirm the central target engagement of peripherally administered LM22A-4, we measured the activation state of TrkB receptors and their downstream signaling. Hippocampal homogenates from mice treated with LM22A-4 for 2 months were subject to western immunoblotting. We found a significant increase in the ratio of phosphorylated TrkBβγδε to full-length TrkB in both WT and Mecp2 HET hippocampi after LM22A-4 treatment (Fig. 1F; n=8 each; P<0.05, one-way ANOVA). Consistently, the ERK and PLCγ cascades were upregulated in WT samples (Fig. S1A; P<0.001) and the PLCγ signaling was activated in Mecp2 HET mice (P<0.05). We also measured the acute effects of LM22A-4 on TrkB phosphorylation in hippocampal slices prepared from male Mecp2 KO mice, where every neuron lacks MeCP2. Interestingly, the levels of phosphorylated TrkB increased significantly after a 30 min exposure to LM22A-4 (500 nM), but only in Mecp2 KO slices (Fig. S1B, left; Mecp2 KO control, n=14; Mecp2 KO LM22A-4, n=13; P<0.001) and not in WT slices (WT control and LM22A-4, n=16 each), which is consistent with the actions of a partial agonist (Massa et al., 2010). Unlike LM22A-4, the full agonist BDNF (250 ng/ml) activated TrkB receptors in slices from both WT (Fig. S1B, right; n=4; P<0.05) and Mecp2 KO mice (n=4; P<0.01). The effect of LM22A-4 on TrkB phosphorylation was completely blocked by the pan-Trk inhibitor K252a (200 nM) (n=12; P<0.01 vs LM22A-4). Treatment with K252a alone had no significant effect on the ratio of phosphorylated TrkB to full-length TrkB (Mecp2 KO K252a, n=6). Additionally, acute LM22A-4 application did not alter TrkB downstream signaling in either genotype (Fig. S1C). Collectively, these data suggest that LM22A-4 improves general phenotype, motor activity and object location memory in Mecp2 HET mice by activating TrkB signaling in the brain.

These data demonstrate that systemic LM22A-4 treatment restores LTP at hippocampal synapses in female Mecp2 HET mice.

**LM22A-4 reduces synaptic strength and network hyperactivity in the hippocampus of female Mecp2 heterozygous mice**

The lack of LTP at hippocampal synapses of male Mecp2 KO mice results from the saturation of their plasticity range by already potentiated synapses (Li et al., 2016). To determine if this is also the case in Mecp2 HET mice, and if LM22A-4 restores LTP by reducing synaptic strength allowing for synaptic potentiation, we performed VSD imaging and obtained the input-output (I-O) relationship of fEPSPs and VSD signals (Fig. 3A). VSD signals in CA1 evoked by increasingly stronger stimulation of Schaffer collaterals are proportional and have similar kinetics to fEPSPs (Fig. 3B). VSD signals larger than two-times the standard deviation of background noise were used to calculate the cumulative percentage of VSD signal amplitudes. Compared with WT control slices (n=18/10), the cumulative percentage of VSD signal amplitudes was significantly shifted to larger amplitudes in Mecp2 KO slices, indicating that excitatory synapses are stronger in female Mecp2 HET mice (Fig. 3C; n=12/9; P<0.01, K-S test), as reported for male Mecp2 KO mice (Calfa et al., 2011a; Li et al., 2012, 2016). LM22A-4 treatment did not affect VSD signals in WT mice (n=20/9), but it significantly shifted the cumulative percentage of VSD signal amplitudes to lower levels in Mecp2 HET slices, making it comparable to WT slices (n=16/10; P<0.001 vs Mecp2 HET control; P<0.05 vs WT LM22A-4). Similar results were obtained for the cumulative percentage of the spatial spread of VSD signals (Fig. 3D).

To directly test the effects of LM22A-4 on synaptic strength, we recorded mEPSCs from CA1 pyramidal neurons in organotypic slice cultures treated with LM22A-4 for 2 days. Whole-cell intracellular recordings were performed in the presence of the sodium channel blocker TTX and the GABAA receptor antagonist picrotoxin (Fig. 4A). Compared with WT neurons (n=9 cultured slices/3 mice), Mecp2 KO neurons show significantly larger mEPSC amplitudes (Fig. 4C; P<0.001) and shorter inter-event intervals (IEIs) (Fig. 4B; n=11/4; P<0.01, K-S test), indicating that excitatory synapses onto CA1 pyramidal neurons are stronger by both pre- and postsynaptic mechanisms of quantal synaptic transmission. Consistent with its effects on the I-O relationship of VSD signals and fEPSPs, LM22A-4 treatment reduced the amplitude and increased the IEI of mEPSCs in Mecp2 KO neurons (n=11/2) to WT levels, without any effects in WT neurons (n=11/4) (Fig. 4B,C; mEPSC amplitude: P<0.001, IEI: P<0.05 vs Mecp2 KO control).

To confirm the effects of LM22A-4 on spontaneous neuronal activity, we imaged spontaneous Ca2+ transients (SCTs) in cultured hippocampal neurons [day in vitro (DIV) 7-13] filled with the Ca2+ indicator Fura-2 (Fig. 4D, Fig. S2A). To measure the effects of LM22A-4 on quantal excitatory synaptic transmission, Ca2+ imaging was performed in the presence of TTX (1 µM). Under these conditions, SCTs reflect the activation of voltage-gated calcium channels (VGCCs) during membrane depolarizations caused by temporally summing mEPSPs. Similar to whole-cell recordings of mEPSCs, the inter-event interval (IEI) of SCTs in Mecp2 KO neurons was shorter compared with that in WT neurons (Fig. 4E,F; P<0.05, Student’s t-test). Also consistent with its effects on mEPSCs, a single localized application of LM22A-4 to Mecp2 KO neurons significantly increased the IEI of SCTs (n=12 cells/5 coverslips; P<0.05), but had no effect on WT neurons (Fig. 4E,F; n=9/3). This effect of LM22A-4 on SCT frequency is similar to that of locally applied BDNF to both WT and Mecp2 KO neurons.
Because these SCTs are due to all-or-none Ca\textsuperscript{2+} spikes driven by VGCCs, there were no differences between WT and Mecp2 KO neurons or any effects of LM22A-4 or BDNF in SCT amplitude (360/380 nm ratio) (Fig. S2C). Further analysis showed that the half-width of SCTs was significantly shorter in Mecp2 KO neurons, which was increased to WT levels after LM22A-4 or BDNF puffing (Fig. S2D; $P<0.05$). The effects on SCT duration are due to differences in decay time, but not rise time (Fig. S2E,F). Taken together, these results suggest that LM22A-4 reduces synaptic strength and tones down network hyperactivity, restoring the optimal range for synaptic plasticity.

**DISCUSSION**

Several recent studies have indicated that the TrkB partial agonist LM22A-4 is a potentially useful therapeutic agent for several neurological diseases. LM22A-4 treatment was shown to promote motor recovery after hypoxic-ischemic stroke in mice (Han et al., 2012), improve motor impairment in the mouse model of Huntington’s disease (Simmons et al., 2013), enhance the recovery of limb function after spinal cord injury in mice (Yu and Wang, 2015), reduce alcohol intake in the mouse model of BDNF polymorphism-related compulsive alcohol drinking (Warnaut et al., 2016) and ameliorate respiratory abnormalities in a mouse model of RTT (Kron et al., 2014; Schmid et al., 2012). Our study provides additional support for the potential use of LM22A-4 in RTT by demonstrating that it reverts deficits in hippocampal-dependent object location memory and long-term synaptic plasticity in female Mecp2 HET mice. LM22A-4 also reduces atypically strong excitatory synaptic transmission and network hyperactivity in the hippocampus of female Mecp2 HET mice, which is likely to restore the proper dynamic range of synaptic plasticity.

BDNF induces TrkB phosphorylation at mouse Tyr\textsuperscript{515} (equivalent to Tyr\textsuperscript{512} in rat TrkA), Tyr\textsuperscript{705/706} and Tyr\textsuperscript{816} (equivalent to Tyr\textsuperscript{817} in human TrkB) in neurons (Minichiello, 2009). TrkB\textsuperscript{Y515} provides a docking site for Shc that leads to activation of PI3K/AKT and MAPK/ERK signaling pathways, TrkB\textsuperscript{Y705/706} is located in the activation loop that is responsible for TrkB autophosphorylation and TrkB\textsuperscript{Y816} creates a docking site for the PLC\textsubscript{γ}/PKC signaling cascade. As a partial agonist of TrkB receptors, LM22A-4 activates TrkB\textsuperscript{Y515}, TrkB\textsuperscript{Y705/706} and TrkB\textsuperscript{Y816} both in control brains and in several mouse models of human neurological disorders (Han et al., 2012; Kajiya et al., 2014; Massa et al., 2010; Schmid et al., 2012; Simmons et al., 2013; Yu and Wang, 2015). Demonstrating central target engagement during our peripheral treatments with LM22A-4, TrkB\textsuperscript{Y816} is activated in the hippocampus of both WT and Mecp2 HET mice, consistent with a robust increase in phosphorylation levels of its downstream target PLC\textsubscript{γ}. Interestingly, although TrkB phosphorylation can be induced by LM22A-4 in the WT hippocampus (Massa et al., 2010), it fails to do so in the WT brainstem (Schmid et al., 2012), suggesting that different brain regions have distinct sensitivity of TrkB phosphorylation sites, or that higher extracellular BDNF levels outcompete a partial agonist (see below).

The significant activation of PLC\textsubscript{γ} signaling in the hippocampus following LM22A-4 treatment may contribute to the restoration of spatial memory and LTP in female Mecp2 HET mice, because PLC\textsubscript{γ} is necessary for LTP maintenance in area CA1 (Minichiello et al., 2002); however, LM22A-4 did not affect hippocampal function in WT mice. There are several possibilities why LM22A-4 could act differently in WT and Mecp2 HET mice. First, BDNF levels are lower in Mecp2-deficient mice than in WT mice (Chang et al., 2006; Li et al., 2012; Schmid et al., 2012; Wang et al., 2006). In WT mice, the efficacy of LM22A-4 may be mitigated by the presence of the full TrkB agonist BDNF, while it can function in Mecp2 HET mice.

**Fig. 2.** LM22A-4 improves LTP at CA3-CA1 synapses in hippocampal slices from female Mecp2 HET mice. (A) Representative images of VSD signals before (top) and 50 min after (bottom) induction of TBS-LTP in WT and Mecp2 HET mice treated with vehicle or LM22A-4. A single stimulation pulse was delivered to Schaffer collaterals to evoke EPSPs and VSD signals in area CA1. (B) Representative traces showing simultaneously recorded VSD signals and field EPSPs before and after TBS-LTP induction. Numbers indicate the time in average plots shown in panels C-E. (C-E) The time course of average VSD signal peak amplitude (C) and spatial spread (D), and field EPSP amplitude (E) during LTP induction in WT and Mecp2 HET mice treated with vehicle or LM22A-4. Arrowheads indicate the start of TBS. Scale bar: 300 µm. Data are mean±s.e.m.
Second, TrkB receptors may have different sensitivity in response to LM22A-4 treatment. Increased neuronal activity in hippocampal cultures results in prolonged activation of TrkB and its downstream signaling (Guo et al., 2014). As in male Mecp2 KO mice (Calfa et al., 2011a; Li et al., 2016), the hippocampus of female HET mice is hyperactive, which may alter the kinetics of TrkB signaling. Indeed, only acute slices from Mecp2 KO mice showed increased TrkB phosphorylation after 30 min exposure to LM22A-4 (Fig. S1B). In addition, only hippocampal neurons from Mecp2 KO mice responded to LM22A-4 by reducing the frequency of spontaneous Ca2+ transients. Third, altered network activity (hyper- or hypoactivity) may affect not only TrkB receptor sensitivity, but also local downstream signaling at synapses.

The short-term actions of BDNF on excitatory synaptic transmission vary depending on brain regions; for example, it: (1) increases evoked field EPSPs at CA3-CA1 synapses (Kang and Schuman, 1995; Ji et al., 2010); (2) decreases evoked EPSCs in sensory neurons within the nucleus of the tractus solitarius in the brainstem (Balkowiec et al., 2000); (3) decreases EPSCs in GABAergic neurons in the visual cortex (Jiang et al., 2004); (4) increases spontaneous quantal mEPSC frequency in hippocampal neurons (Lessmann et al., 1994; Amaral and Pozzo-Miller, 2012); and (5) has no effect at all on field EPSPs and evoked EPSCs at CA3-CA1 synapses (Patterson et al., 1996; Frerking et al., 1998; Gottschalk et al., 1998). Similarly, the long-term effects of BDNF vary; it: (1) increases EPSCs in autaptic cultures of hippocampal pyramidal neurons (Sherwood and Lo, 1999); (2) decreases AMPAR expression in medium spiny neurons of nucleus accumbens (Reimers et al., 2014); (3) increases spontaneous mEPSC frequency, synaptic vesicle docking at active zones, and spine density in hippocampal pyramidal neurons (Tyler and Pozzo-Miller, 2001); and (4) has no effect on evoked EPSCs in pyramidal neurons of rat visual cortical cultures (Rutherford et al., 1998). Such different actions of BDNF on excitatory synaptic transmission may be due to different levels of network activity in each brain region or experimental condition. For example, during prolonged neuronal activity induced by the GABAA receptor antagonist bicuculline, the BDNF scavenger TrkB-Fc prevents scaling down of surface expression of AMPARs (Reimers et al., 2014). Furthermore, BDNF prevents the scaling up of mEPSC amplitude induced by prolonged activity blockade with TTX, while the BDNF scavenger TrkB-Fc mimics scaling-up of mEPSC amplitude during homeostatic synaptic plasticity (Rutherford et al., 1998). Similar to the higher levels of AMPAR during the homeostatic synaptic plasticity,
Mecp2-deficient mice have higher surface levels of AMPARs at synapses, which saturates the dynamic range of synaptic plasticity (Li et al., 2016). The actions of LM22A-4 at hippocampal synapses of female Mecp2 HET mice may reflect the restoration of activity-dependent AMPAR endocytosis, resulting in smaller evoked EPSPs, mEPSCs and spontaneous Ca²⁺ transients driven by mEPSPs. Alternatively, LM22A-4 may enhance TrkB-dependent maturation of GABAergic neurons and synapses, resulting in improved synaptic inhibition and hippocampal network stability.

In conclusion, we present evidence that chronic peripheral LM22A-4 treatment in female Mecp2 HET mice improves motor function and hippocampal-dependent object location memory, and restores hippocampal long-term synaptic plasticity deficits. LM22A-4 exerts these effects by subduing excitatory synaptic transmission and network activity to levels amenable for the induction of synaptic plasticity and behavioral learning and memory. Our findings add to the growing body of literature supporting the high therapeutic potential of the TrkB ligand LM22A-4 for the treatment of RTT and other diseases associated with lower levels of BDNF.

**MATERIALS AND METHODS**

**Animals**

Breeding pairs of mice lacking exon 3 of Mecp2 (B6.Cg-Mecp2tm1.1Jae, Jaenisch strain in a pure C57BL/6 background) (Chen et al., 2001) were purchased from the Mutant Mouse Regional Resource Center at the University of California, Davis. A colony was established at the University of Alabama at Birmingham by mating WT C57BL/6 male mice with heterozygous Mecp2tm1.1Jae female mice (Mecp2 HET), as recommended by the supplier. Genotyping was performed by PCR of DNA samples from tail clips. Hemizygous Mecp2tm1.1Jae males (Mecp2 KO), develop typically until 5-6 weeks of age, when they begin to exhibit RTT-like motor symptoms, such as hypoactivity, hind limb clasping and reflex impairments. Acute slices prepared from male symptomatic Mecp2 KO mice were used for in vitro treatment. Female Mecp2 HET mice, which develop RTT-like symptoms between 2-3 months of life (Samaco et al., 2013), were used for in vivo treatment because they represent the best model for preclinical studies (Katz et al., 2012). Animals were handled and housed according to the Committee on Laboratory Animal Resources of the National Institutes of Health; all experimental protocols were reviewed annually and approved by the Institutional Animals Care and Use Committee of the University of Alabama at Birmingham.
**In vivo LM22A-4 treatment**
LM22A-4 was prepared fresh daily. Female Mecp2 HET mice and their age-matched WT littermates (~4 months old) received intraperitoneal (i.p.) injections of either sterile LM22A-4 (50 mg/kg) or vehicle (0.9% NaCl) twice daily for 1 or 2 months, following an established dosing regime (Schmid et al., 2012). Mice were randomly assigned to each treatment.

**General phenotype**
General phenotype was evaluated according to an established protocol (Guy et al., 2007). We visually scored RTT-like general symptoms consisting of ill-groomed condition, reduced motility, imbalanced gait, hind limb claspings, irregular breathing and tremor. Each category was scored every week during the treatment with LM22A-4 or vehicle according to their symptom severity (0: absent; 1: moderate; 2: severe), and the aggregated value was then calculated to reflect general phenotypes during disease progression. We scored the following features: (A) General condition: 0: clean and sleek hair, limpid eyes; 1: ungroomed hair, opaque eyes; 2: severe piloerection, narrowing eye. (B) Motility: 0: free and steady movement; 1: less movement, frequent freezing; 2: almost no voluntary movement. (C) Gait: 0: normal stance; 1: wider spread during the movement of the hind legs; 2: severe walking abnormality, low pelvic elevation. (D) Hind limb claspings: 0: legs spreading; 1: one leg frequently drawing close to the body; 2: two legs always tightening close to the body. (E) Breathing: 0: normal breathing; 1: occasional breathing stops and gasping; 2: frequent breathing stops and gasping. (F) Tremor: 0: no tremor; 1: occasional mild tremor; 2: continuous tremor.

**Open field test**
WT and Mecp2 HET mice that received either LM22A-4 or vehicle for 2 months were placed in the center of a 60×60 cm open arena. Following 10 min habituation, mice were imaged for 10 min with an IR-sensitive Gigabit Ethernet video camera (ace acA780-75gm, Basler). Recorded activity was analyzed for the distance that these mice traveled. The open field arena was cleaned with 70% ethanol between each trial.

**Dowel crossings**
Control or LM22A-4-treated mice were placed on the center of a dowel suspended between two platforms. The time to successfully cross the dowel without falling off was recorded for each mouse. If the mouse failed, the mouse was placed back to the center of the dowel. The test lasted 2 min beginning when the mouse was placed on the dowel.

**Object location test**
The object location test for mice was adapted from an established protocol (Munir et al., 2007). Mice were habituated for 3 consecutive days before testing, by allowing them to freely explore the empty test field (30×40 cm) for 5 min. During the acquisition phase, one mouse was allowed 5 min to freely explore 2 identical objects placed equidistant from each other and from the walls. The mouse was then returned to its home cage for a 2 h consolidation phase. During the test trial, the mouse was returned to the open field where one object had been moved to a new location, and allowed to freely explore the objects for 5 min. The new location of the displaced object was counterbalanced for each mouse to prevent the use of spatial cues outside the test field. The acquisition and test phases were imaged with an IR-sensitive Gigabit Ethernet video camera and movies saved directly to a hard drive for offline analyses (ImageJ). The time spent exploring each object in the test phase was scored to calculate a location preference index as $T_{d}/T_{t}+T_{d}$, where $T_{d}$ is the time spent exploring the displaced object, and $T_{t}$ the time spent exploring the non-displaced object. Exploration was defined as pointing the nose towards the object at a distance of <1 cm and/or touching with the nose; circling or climbing the object was not considered exploration.

**Western immunoblotting**
For short-term drug treatment in acute brain slices, mice were anesthetized with isoflurane, and the brain was rapidly removed and placed in ice-cold cutting artificial cerebrospinal fluid (aCSF) (87 mM NaCl, 2.5 mM KCl, 0.5 mM CaCl$_2$, 7 mM MgCl$_2$, 1.25 mM NaH$_2$PO$_4$, 25 mM NaHCO$_3$, 25 mM glucose and 75 mM sucrose, bubbled with 95% O$_2$/5% CO$_2$). The brain was cut transversely at 300 μm using a vibrating blade microtome (VT1200S, Leica) and slices were transferred to standard aCSF (125 mM NaCl, 2.5 mM KCl, 2 mM CaCl$_2$, 1 mM MgCl$_2$, 1.25 mM NaH$_2$PO$_4$, 25 mM NaHCO$_3$, and 25 mM glucose, bubbled with 95% O$_2$/5% CO$_2$) at 32°C for 30 min, and then allowed to recover at room temperature (24°C) for 1 h prior to drug exposure. Slices were then randomly assigned to treatment groups: control, LM22A-4 (500 nM), recombinant human BDNF (250 ng/ml, Promega, G1491), K252a (200 nM, Calbiochem, 420298), LM22A-4 +K252a, and BDNF+K252a. Two to four slices per mouse were perfused under each treatment condition at 4-6 ml/min for 30 min. Following treatment, the hippocampus was quickly dissected from each slice and rapidly frozen on dry ice. For sample preparation from female WT and Mecp2 HET mice receiving in vivo treatment, hippocampi were dissected after the last injection and rapidly frozen on dry ice.

**Hippocampal samples** were homogenized with a sonicator on ice in Nonidet P-40 buffer (20 mM Tris-HCl at pH 8.0, 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, 2 mM EDTA) containing protease inhibitor and phosphatase inhibitor (Sigma). The homogenates were agitated for 2 h and then centrifuged at 12,000 g for 20 min at 4°C. The supernatants were aspirated and protein concentrations determined by the Lowry method. Equal amounts of protein sample were denatured in loading buffer (125 mM Tris-HCl at pH 6.8, 20% glycerol, 6% SDS, and 5% 2-mercaptoethanol), boiled for 3 min, and subjected to SDS-PAGE. Proteins were then transferred to PVDF membranes and blocked with 5% nonfat milk in TBST (20 mM Tris-HCl at pH 7.6, 150 mM NaCl and 0.1% Tween-20) for 1 h. Membranes were incubated with primary antibodies against phospho-TrkB ($^{\gamma}$Tyr1811) (1:500, Abcam, ab75173), total-TrkB (1:200, Santa Cruz, SC20542), phospho-ERK (1:1000, Cell Signaling, 9101S), total ERK (1:2000, Cell Signaling, 4695S), phospho-AKT (1:1000, Cell Signaling, 9271S), total AKT (1:2000, Cell Signaling, 9713S), and total PLCγ (1:1000, Cell Signaling, 2822S), and then with corresponding HRP-conjugated secondary antibodies (Santa Cruz). The protein bands were detected using the Pierce ECL Substrate (Thermo Fisher Scientific) and signals were captured on autoradiography film. The membranes were re-probed for the loading control β-actin (Thermo Fisher Scientific) and detected using an Odyssey infrared imaging system after incubation with fluorescent secondary antibodies (LI-COR Bioscience). Protein levels of bands were quantified using computer-assisted densitometry; only non-saturated bands were analyzed. Ratios of all bands to the loading controls were obtained, values were normalized to control, and then the ratios of phospho-TrkB to full-length TrkB, phospho-ERK to total ERK, phospho-AKT to total AKT, and phospho-PLCγ to total PLCγ were calculated as measures of activation of TrkB receptors and their intracellular signaling cascade.

**Organotypic slice cultures**
Slices were prepared from male Mecp2 KO mice and WT littermates at postnatal day 5-7 (P5-7), as described (Chapleau et al., 2009). Hippocampal slices 500 μm thick were plated on tissue culture plate inserts (Millicell-CM) in 6-well plates with serum-containing culture medium consisting of Neurobasal-A without Phenol Red (Invitrogen), 20% heat-inactivated equine serum (Invitrogen), B27 supplement (Invitrogen), 0.5 mM L-glutamine (Invitrogen) and placed in an incubator at 36°C, 5% CO$_2$, 90% relative humidity. Serum was titrated out over 3 days in vitro and treatments were made in serum-free culture medium (Chapleau et al., 2008). At DIV 10-12, medium was aspirated from culture wells and replaced with serum-free medium containing LM22A-4 (500 nM), followed by gentle application of 50 μl of drug-containing medium on top of each hippocampal slice. After 2 days of LM22A-4 treatment, slices were transferred to an immersion chamber for whole-cell patch clamping.

**High-speed VSD imaging and electrophysiology**
Acute hippocampal slices from female WT and Mecp2 HET mice that received treatment for 2 months were prepared as described above. After recovery, individual slices were stained with the voltage-sensitive fluorescent dye RH414 (30 μM in aCSF, Anaspec) for 1 h at room temperature, and transferred to an immersion chamber continuously perfused (2 ml/min) with aCSF at 32°C and saturated with 95%O$_2$/5% CO$_2$. VSD signals and extracellular field EPSPs were evoked in CA1
12 mm poly-L-lysine/laminin-coated glass coverslips, and immersed in (CoolSNAP, Photometrics). Ca2+ signals were imaged in the presence of emission at >510 nm was detected with a cooled CCD camera light from a monochromator (Polychrome-II, TILL Photonics), and its with a 40×0.75NA water immersion objective. A 16 min movie with 4 s incubated with Fura-2 AM at room temperature for 30 min. The coverslips the working solution (5 µM). Neurons (DIV 7-13) on the coverslips were culture medium changed every 3-4 days.

(ROIs) were drawn on individual neuronal cell bodies for Ca2+ signals and a cell-free region for background subtraction. Spontaneous Ca2+ inter-event intervals were calculated.

The inter-event interval, amplitude, half-width, rise time and decay time of SCTs were calculated.

Funding
This work was supported by postdoctoral fellowship IRSF-2824 from the International Rett Syndrome Foundation (W.L.), the National Institutes of Health (NS-055027 and HD-074418 to L.P.-M.) and the Rett Syndrome Research Trust (L.P.-M.).

Supplementary information
Supplementary information available online at http://dmm.biologists.org/lookup/doi/10.1242/dmm.029959

References
Abuhzaira, L., Makedonski, K., Kaufman, Y., Razin, A. and Shemer, R. (2007). MeCP2 deficiency in the brain decreases BDNF levels by REST/CoREST-mediated repression and increases TRKB production. Epigenetics 2, 214-222.

Amaral, M. D. and Pozzo-Miller, L. (2007). TRPC3 channels are necessary for brain-derived neurotrophic factor to activate a nonselective cationic current and to induce dendritic spine formation. J. Neurosci. 27, 5179-5189.

Amaral, M. D. and Pozzo-Miller, L. (2012). Intracellular Ca2+ stores and Ca2+ influx are both required for BDNF to rapidly increase quantal vesicular transmitter release. Neur. Plast. 2012, 203536.

Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francee, U. and Zoghbi, H. Y. (1999). Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185-188.

Balakowiec, A., Kunze, D. L. and Katz, D. M. (2000). Brain-derived neurotrophic factor acutely inhibits AMPA-mediated currents in developing sensory relay neurons. J. Neurosci. 20, 1904-1911.

Barker, G. R. I. and Warburton, E. C. (2011). When is the hippocampus involved in recognition memory? J. Neurosci. 31, 10721-10731.

Calfa, G., Hablitz, J. J. and Pozzo-Miller, L. (2011a). Network hyperexcitability in hippocampal slices from MeCP2 mutant mice revealed by voltage-sensitive dye imaging. J. Neurophysiol. 105, 1768-1784.

Calaf, G., Percy, A. K. and Pozzo-Miller, L. (2011b). Experimental models of Rett syndrome based on MeCP2 dysfunction. Exp. Biol. Med. 236, 3-19.

Chahrour, M., Jung, S. Y., Shaw, C., Zhou, X., Wong, S. T. C., Qin, J. and Zoghbi, H. Y. (2008). MeCP2, a key contributor to neuronal developmental processes, and represses transcription. Science 320, 1224-1229.

Chang, P. Y. and Jackson, M. B. (2006). Heterogeneous spatial patterns of long-term potentiation in rat hippocampal slices. J. Physiol. 576, 427-443.

Chang, Q., Khare, G., Dani, V., Nelson, S. and Jaenisch, R. (2008). The disease progression of MeCP2 mutant mice is affected by the level of BDNF expression. Neuron 49, 341-348.

Chapleau, C. A., Carlo, M. E., Laroie, J. L. and Pozzo-Miller, L. (2008). The actions of BDNF on dendritic spine density and morphology in organotypic slice cultures depend on the presence of serum in culture media. J. Neurosci. Methods 169, 182-190.

Chapleau, C. A., Calfa, G. D., Lane, M. C., Albertson, A. J., Laroie, J. L., Kudo, S., Armstrong, D. L., Percy, A. K. and Pozzo-Miller, L. (2009). Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MeCP2 mutations. Neuronb1, 219-233.

Chen, R. Z., Akbarian, S., Tudor, M. and Jaenisch, R. (2001). Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 27, 327-331.

Chen, W. G., Chang, Q., Lin, Y., Meissner, A., West, A. E., Griffith, E. C., Jaenisch, R. and Greenberg, M. E. (2003). Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302, 885-889.

Deng, V., Matagne, V., Banine, F., Freking, M., Ohliger, P., Budden, S., Pevsner, J., Dissen, G. A., Sherman, L. S. and Ojeda, S. R. (2007). FXYD1 is an MeCP2
target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. *Hum. Mol. Genet.* **16**, 640-650.

Frerking, M., Malenka, R. C. and Nicoll, R. A. (1998). Brain-derived neurotrophic factor (BDNF) modulates inhibitory, but not excitatory, transmission in the CA1 region of the hippocampus. *J. Neurophysiol.* **80**, 3383-3386.

Gottschalk, W., Pozzo-Miller, L. D., Figuero, A. and Lu, B. (1998). Presynaptic modulation of synaptic transmission and plasticity by brain-derived neurotrophic factor in the developing hippocampus. *J. Neurosci.* **18**, 6830-6839.

Guo, W., Ji, Y., Wang, S., Sun, Y. and Lu, B. (2014). Neuronal activity alters BDNF–TrkB signaling kinetics and downstream functions. *J. Cell Sci.* **127**, 2249-2260.

Guy, J., Gan, J., Selfridge, J., Cobb, S. and Bird, A. (2007). Reversal of neurological defects in a mouse model of Rett syndrome. *Science* **315**, 1143-1147.

Han, J., Pollak, J., Yang, T., Siddiqui, M. R., Doyle, K. P., Taravosh-Lahn, K., Lauterborn, J. C., Lynch, G., Vanderklish, P., Arai, A. and Gall, C. M. Kron, M., Lang, M., Adams, I. T., Sceniak, M., Longo, F. and Katz, D. M. (2002). Mechanism of TrkB-mediated hippocampal long-term potentiation. *Neuron* **36**, 121-137.

Murall, T., Okuda, S., Tanaka, T. and Ohta, H. (2007). Characteristics of object location memory in mice: Behavioral and pharmacological studies. *Physiol. Behav.* **90**, 116-124.

Neul, J. L., Kaufmann, W. E., Glaze, D. G., Christodoulou, J., Clarke, A. J., Bahl-Buisson, N., Leonard, H., Bailey, M. E. S., Schanen, N. C., Zappella, M. et al.; Rett Syndrome Consortium. (2010). Rett syndrome: revised diagnostic criteria and nomenclature. *Ann. Neurol.* **68**, 944-950.

Ogier, M., Wang, H., Hong, E., Wang, Q., Greenberg, M. E. and Katz, D. M. (2007). Brain-derived neurotrophic factor expression and respiratory function improve after amphetamine treatment in a mouse model of Rett syndrome. *J. Neurosci.* **27**, 10912-10917.

Park, H. and Poo, M.-M. (2013). Neurotrophin regulation of neural circuit development and function. *Nat. Rev. Neurosci.* **14**, 7-23.

Patterson, S. L., Abel, T., Deuel, T. A. S., Martin, K. C., Rose, J. C. and Kandel, E. R. (1996). Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. *Neuron* **16**, 1137-1145.

Percy, A. K. (2011). Rett syndrome: exploring the autism link. *Arch. Neurol.* **68**, 985-989.

Reimers, J. M., Loveth, J. A. and Wolf, M. E. (2014). BDNF contributes to both rapid and homeostatic alterations in AMPA receptor surface expression in nucleus accumbens medium spiny neurons. *Nat. Neurosci.* **17**, 509-519.

Rutherford, L. C., Nelson, S. B. and Turrigiano, G. G. (1998). BDNF has opposite effects on the quantal amplitude of pyramidal neuron and interneuron excitatory synapses. *Neuron* **21**, 521-530.

Samaco, R. C., McGraw, C. M., Ward, C. S., Sun, Y., Neul, J. L. and Zoghbi, H. Y. (2013). Female Mecp2<sup>−/−</sup> mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies. *Hum. Mol. Genet.* **22**, 96-109.

Schmid, D. A., Yang, T., Ogier, M., Adams, I., Mirakhur, Y., Wang, Q., Massa, S. L., Longo, F. M. and Katz, D. M. (2012). A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. *J. Neurosci.* **32**, 1803-1810.

Sherwood, N. T. and Lo, D. C. (1999). Long-term enhancement of central synaptic transmission by chronic brain-derived neurotrophic factor treatment. *J. Neurosci.* **19**, 7025-7036.

Simmons, D. A., Belichenko, N. P., Yang, T., Condon, C., Monbureau, M., Shamloo, M., Jing, D., Massa, S. M. and Longo, F. M. (2013). A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington’s disease. *J. Neurosci.* **33**, 18712-18727.

Tyler, W. J. and Pozzo-Miller, L. D. (2001). BDNF enhances synaptic neurotransmitter release and increases the number of docked vesicles at the active zones of hippocampal excitatory synapses. *J. Neurosci.* **21**, 4249-4258.

Wang, H., Chan, S.-A., Ogier, M., Hellard, D., Wang, Q., Smith, C. and Katz, D. M. (2006). Dysregulation of brain-derived neurotrophic factor expression and neurosecretory function in Mecp2 null mice. *J. Neurosci.* **26**, 10911-10915.

Warnaart, V., Darco, E., Morisot, N., Phamluong, K., Wilbrecht, L., Massa, S. M., Longo, F. M. and Ron, D. (2016). The BDNF valine 68 to methionine polymorphism increases compulsive alcohol drinking in mice that is reversed by trkB-Fc and mGluR1 receptor kinase B activation. *Biol. Psychiatry* **79**, 463-473.

Yu, G. and Wang, W. (2015). Protective effects of LM22A-4 on injured spinal cord nerves. *Int. J. Clin. Exp. Pathol.* **8**, 6526-6532.